nach oben

Lung

Erschienen in:

01.06.2009

Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha

verfasst von: Brian Casserly, Walter Donat

Erschienen in: Lung | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

The most characteristic feature of airway inflammation in cystic fibrosis (CF) is the persistent infiltration of massive numbers of neutrophils. Although inflammation is primarily a protective response to injury, it has the potential to cause considerable harm when it is excessive. Recent recognition of the prominent role of inflammation has prompted the investigation of treatments designed to control inflammation in the CF lung. We report a 35-year-old man with abrupt stabilization of his rapidly progressive CF and forced expiratory volume (FEV1) after starting infliximab for his rheumatoid arthritis. This effect was sustained for 8 years while continuing to use twice-monthly infliximab.

Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951. doi:10.1164/rccm.200304-505SO PubMedCrossRef

Brown RK, Kelly FJ (1994) Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 49(8):738–742. doi:10.1136/thx.49.8.738 PubMedCrossRef

Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15):1066–1071. doi:10.1056/NEJM199704103361506 PubMedCrossRef

Bonfield TL, Panuska JR, Konstan MW et al (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152(6 Pt 1):2111–2118PubMed

Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN et al (1998) Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 4(5):615–618. doi:10.1038/nm0598-615 PubMedCrossRef

Antoniu SA (2006) Etanercept for refractory asthma therapy. Expert Opin Investig Drugs 15(10):1279–1281. doi:10.1517/13543784.15.10.1279 PubMedCrossRef

Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN (2005) Anti-TNF therapy: where have we got to in 2005? J Autoimmun 25:26–28. doi:10.1016/j.jaut.2005.09.006 SupplPubMedCrossRef

Tracey KJ, Fong Y, Hesse DG et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662–664. doi:10.1038/330662a0 PubMedCrossRef

Guilbault C, Saeed Z, Downey GP, Radzioch D (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36(1):1–7. doi:10.1165/rcmb.2006-0184TR PubMedCrossRef

10.

Auerbach HS, Williams M, Kirkpatrick JA, Colten HR (1985) Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2(8457):686–688. doi:10.1016/S0140-6736(85)92929-0 PubMedCrossRef

11.

Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126(4):515–523. doi:10.1016/S0022-3476(95)70343-8 PubMedCrossRef

12.

Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332(13):848–854. doi:10.1056/NEJM199503303321303 PubMedCrossRef

13.

Konstan MW, Schluchter MD, Xue W, Davis PB (2007) Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176(11):1084–1089. doi:10.1164/rccm.200702-181OC PubMedCrossRef

14.

Chmiel J, Konstan MW (2007) Inflammation and anti-Inflammatory therapies for cystic fibrosis. Clin Chest Med 28(2):331–346. doi:10.1016/j.ccm.2007.02.002 PubMedCrossRef

15.

Yarden J, Radojkovic D, De Boeck K et al (2005) Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60(4):320–325. doi:10.1136/thx.2004.025262 PubMedCrossRef

Titel: Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha
verfasst von: Brian Casserly
Walter Donat
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Lung / Ausgabe 3/2009
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-009-9138-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Costims – das nächste heiße Ding in der Krebstherapie?

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Intravenous Immunoglobulin Therapy for Refractory Interstitial Lung Disease Associated with Polymyositis/Dermatomyositis

Toll-Like Receptor 2 Gene Polymorphisms Arg677Trp and Arg753Gln in Chronic Obstructive Pulmonary Disease

Idiopathic Diaphragmatic Paralysis: Bell’s Palsy of the Diaphragm?

Upregulation of ADAM8 in the Airways of Mice with Allergic Bronchial Asthma

TGF-β1 Induces Human Bronchial Epithelial Cell-to-Mesenchymal Transition in Vitro

Array CGH Reveals Genomic Aberrations in Human Emphysema

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Costims – das nächste heiße Ding in der Krebstherapie?

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin